Observational studyPloS one2026
Impact of an infectious disease specialist-led antimicrobial stewardship program and consultations during multiple antimicrobial shortages: A bayesian structural time-series analysis.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since antimicrobial shortages are becoming common owing to manufacturing issues and sudden demand, individualized antimicrobial optimization by infectious disease specialists is essential. We evaluated the effects of a 12-month antimicrobial stewardship program at a university-affiliated hospital in Japan during antimicrobial shortages. In this single-center retrospective observational study, from April 1, 2023, to March 31, 2025, we compared the pre-intervention (antimicrobial stewardship program without infectious disease specialists) and post-intervention (antimicrobial stewardship program with infectious disease specialists and formal consultation service) periods. The evaluated outcomes included antimicrobial use, microbiological indicators (number of culture specimens submitted and hospital-acquired resistant organisms), patient outcomes (in-hospital mortality and length of hospital stay), and antimicrobial costs. A Bayesian structural time-series analysis adjusted for seasonality was used to assess intervention effects. In total, 24,601 inpatients were included (11,782 before intervention and 12,819 after). Shortages affected nine intravenous and two oral antibiotics. The antimicrobial stewardship program team provided 1110 feedback instances (acceptance rate, 74.1%) and conducted 172 infectious disease consultations in the post-intervention period. Carbapenem use, antipseudomonal agent use, incidence of carbapenem-resistant Pseudomonas aeruginosa, and the cost of carbapenems per patient-day significantly decreased. Narrow-spectrum antibiotic use, anti-methicillin-resistant Staphylococcus aureus agent use, all intravenous antimicrobial use, total intravenous and oral antimicrobials, and the number of inpatient specimens were significantly increased. All antimicrobial costs, in-hospital mortality, and length of hospital stay remained unchanged. Antimicrobial stewardship program supported by infectious disease specialists/consultants significantly reduced carbapenem and antipseudomonal agent use without negatively affecting patient outcomes. These findings highlight infectious disease specialists' critical role in supporting effective antimicrobial stewardship programs, particularly during limited antimicrobial supply and increased clinical complexity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.